A	DT
translational	JJ
preclinical	JJ
model	NN
of	IN
interstitial	JJ
pulmonary	JJ
fibrosis	NN
and	CC
pulmonary	JJ
hypertension	NN
:	:
mechanistic	JJ
pathways	NNS
driving	VBG
disease	NN
pathophysiology	NN
.	.

Idiopathic	JJ
pulmonary	JJ
fibrosis	NN
(	(
IPF	NN
)	)
is	VBZ
a	DT
chronic	JJ
progressive	JJ
interstitial	JJ
lung	NN
disease	NN
,	,
in	IN
which	WDT
a	DT
decline	NN
in	IN
patient	NN
prognosis	NN
is	VBZ
frequently	RB
associated	VBN
with	IN
the	DT
onset	NN
of	IN
pulmonary	JJ
hypertension	NN
(	(
PH	NN
)	)
.	.

Animal	NN
models	NNS
exhibiting	VBG
principle	NN
pathophysiological	JJ
features	NNS
of	IN
IPF	NN
and	CC
PH	NN
could	MD
provide	VB
greater	JJR
insight	NN
into	IN
mechanistic	JJ
pathways	NNS
underlying	VBG
disease	NN
progression	NN
and	CC
a	DT
means	NN
for	IN
evaluating	VBG
novel	JJ
therapeutic	JJ
approaches	NNS
for	IN
intervention	NN
.	.

Here	RB
,	,
we	PRP
describe	VBP
an	DT
in	FW
vivo	FW
disease	NN
model	NN
,	,
in	IN
which	WDT
animals	NNS
develop	VB
progressive	JJ
interstitial	JJ
pulmonary	JJ
fibrosis	NN
and	CC
associated	VBN
PH	NN
,	,
as	IN
defined	VBN
by	IN
the	DT
presence	NN
of	IN
fibrotic	JJ
foci	NNS
adjacent	JJ
to	TO
areas	NNS
of	IN
alveolar	JJ
injury	NN
and	CC
remodeling	NN
of	IN
the	DT
pulmonary	JJ
vasculature	NN
.	.

Associated	VBN
changes	NNS
in	IN
physiological	JJ
parameters	NNS
included	VBD
a	DT
decline	NN
in	IN
lung	NN
function	NN
and	CC
increase	NN
in	IN
mean	JJ
pulmonary	JJ
arterial	JJ
pressure	NN
(	(
mPAP	NN
)	)
>	JJR
25	CD
mmHg	NN
.	.

The	DT
early	JJ
fibrotic	JJ
pathology	NN
is	VBZ
associated	VBN
with	IN
a	DT
profibrogenic	JJ
microenvironment	NN
,	,
elevated	JJ
levels	NNS
of	IN
the	DT
matrix	NN
metalloproteases	NNS
,	,
MMP-2	NN
,	,
MMP-7	NN
,	,
and	CC
MMP-12	NN
,	,
TIMP-1	NN
,	,
the	DT
chemoattractant	NN
and	CC
mitogen	NN
,	,
PDGF-b	NN
,	,
and	CC
the	DT
chemokines	NNS
CCL2	NN
and	CC
CXCL12	NN
,	,
that	WDT
are	VBP
associated	VBN
with	IN
the	DT
recruitment	NN
of	IN
macrophages	NNS
,	,
mast	NN
cells	NNS
,	,
and	CC
fibrocytes	NNS
.	.

Principle	NN
mechanistic	JJ
pathways	NNS
associated	VBN
with	IN
disease	NN
pathogenesis	NN
are	VBP
upregulated	VBN
in	IN
the	DT
lungs	NNS
and	CC
pulmonary	JJ
arteries	NNS
,	,
with	IN
sustained	JJ
increases	NNS
in	IN
gene	NN
transcripts	NNS
for	IN
the	DT
profibrotic	JJ
mediator	NN
TGF-b1	NN
and	CC
components	NNS
of	IN
the	DT
TGF-b	NN
signaling	NN
pathway	NN
;	:
PAI-1	NN
,	,
Nox-4	NN
,	,
and	CC
HIF-1a	NN
.	.

Therapeutic	JJ
treatment	NN
with	IN
the	DT
ALK-5	NN
/	:
TGF-b	NN
RI	NN
inhibitor	NN
SB-525334	NN
reversed	VBD
established	JJ
pulmonary	JJ
fibrosis	NN
and	CC
associated	VBN
vascular	JJ
remodeling	NN
,	,
leading	VBG
to	TO
normalization	NN
in	IN
clinically	RB
translatable	JJ
physiological	JJ
parameters	NNS
including	VBG
lung	NN
function	NN
and	CC
hemodynamic	JJ
measurements	NNS
of	IN
mPAP	NN
.	.

These	DT
studies	NNS
highlight	VBP
the	DT
application	NN
of	IN
this	DT
model	NN
in	IN
validating	VBG
potential	JJ
approaches	NNS
for	IN
targeting	VBG
common	JJ
mechanistic	JJ
pathways	NNS
driving	VBG
disease	NN
pathogenesis	NN
.	.

